Maxigen Biotech (TPE:1783) ROCE %: 37.22% (As of Dec. 2025)

What is Maxigen Biotech ROCE %?

Maxigen Biotech TPE:1783 -1.55% 87 ROCE % is 37.22% as of Dec. 2025. GuruFocus rates TPE:1783 with a GF Score™ of 87/100 and a GF Value™ of NT$60.99 (Significantly Undervalued).

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Maxigen Biotech's annualized ROCE % for the quarter that ended in Dec. 2025 was 37.22%.

Maxigen Biotech (TPE:1783) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Maxigen Biotech ROCE % Related Terms

Maxigen Biotech ROCE % Historical Data

* Premium members only.

The historical data trend for Maxigen Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maxigen Biotech ROCE % Chart

Maxigen Biotech Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

9.67

13.56

11.29

16.47

20.88

Maxigen Biotech Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
ROCE %	Get a 7-Day Free Trial															29.79	10.91	19.02	15.46	37.22

87GF Score

Maxigen Biotech Inc TPE:1783

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Maxigen Biotech ROCE % Calculation

Maxigen Biotech's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	304.931	/	( ( (1582.489 - 205.869)	+	(1893.142 - 349.109) )	/ 2 )
	=	304.931	/	( (1376.62	+	1544.033)	/ 2 )
	=	304.931	/	1460.3265
	=	20.88 %

Maxigen Biotech's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2025 )		(Q: Sep. 2025 )		(Q: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2025 )		(Q: Sep. 2025 )		(Q: Dec. 2025 )
	=	562.92	/	( ( (1707.558 - 226.545)	+	(1893.142 - 349.109) )	/ 2 )
	=	562.92	/	( ( 1481.013	+	1544.033 )	/ 2 )
	=	562.92	/	1512.523
	=	37.22 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 37.22% mean?

Maxigen Biotech (TPE:1783) has a ROCE % of 37.22% as of Dec. 2025.

Is Maxigen Biotech's ROCE % too high?

Maxigen Biotech's current ROCE % is 37.22%. The Medical Devices & Instruments industry median ROCE % is 2.23. Maxigen Biotech's value of 37.22% is 1569.1% above this industry median. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Maxigen Biotech's ROCE % compare to ISRG and BDX?

Maxigen Biotech's ROCE % of 37.22% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Maxigen Biotech's value of 37.22% is 1569.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maxigen Biotech's current ROCE % of 37.22% is 1569.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maxigen Biotech's current ROCE % is 37.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Maxigen Biotech stock overvalued right now?

Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$60.99, compared to a current price of NT$38.10 — trading 37.5% below its estimated fair value. The current ROCE % is 37.22% and 1569.1% above the Medical Devices & Instruments industry median of 2.23. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current ROCE % is 37.22% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Maxigen Biotech (TPE:1783) Overvalued in 2026?

Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued. The current stock price of NT$38.10 is trading 37.5% below its estimated GF Value™ of NT$60.99. GuruFocus considers Maxigen Biotech to be Significantly Undervalued.

Key valuation signals for TPE:1783:

ROCE %: 37.22%
GF Value™: NT$60.99 vs. price of NT$38.10 (37.5% below fair value)
GF Score™: 87/100
Industry Position: 1569.1% above the Medical Devices & Instruments median

No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Maxigen Biotech Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies ROCO:6612 TPE:1752 TPE:1786 TPE:4737 ROCO:1565 ROCO:4111 ROCO:6527 ROCO:4116 ROCO:5312 ROCO:6730 ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST TSE:4543 XPAR:DIM

Address No.88, Keji 1st Road, Guishan District, Taoyuan City, TWN, 333

Website https://www.mbi-bio.com

Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.

87GF Score

Get the complete analysis for TPE:1783

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$38.10

Price

NT$60.99

GF Value

View TPE:1783 Analysis

See ROCE % data for all stocks →